

EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

Company

2024/06/14 17:35:04



Price

8.40 EUR

Difference ▲ 0.72% (0.06)



Contact Details

EVOTEC SE

Tel: +49-40-56081-0

--

Fax:

+49-40-56081-222

Manfred Eigen Campus, Essener
Bogen 7

Web:

<http://evotec.com>

22419 Hamburg

E-mail:

info@evotec.com

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 903,162,000 | | 1,073,671,000 | | 1,100,940,000 | |
| Common stock capital | | 177,186,000 | | 176,953,000 | | 176,608,000 |
| Fixed assets | 1,395,891,000 | | 1,232,464,000 | | 1,175,323,000 | |
| Equity capital of a company | | 1,119,908,000 | | 1,187,184,000 | | 1,377,685,000 |
| Cash and cash equivalents | 510,909,000 | | 415,155,000 | | 699,326,000 | |
| Accrued liabilities | | 16,062,000 | | 16,427,000 | | 18,021,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 464,573,000 | | 337,706,000 | | 324,516,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 714,572,000 | | 781,245,000 | | 574,062,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 156,676,000 | | 207,113,000 | | 34,943,000 |
| Total assets | 2,299,053,000 | 2,299,053,000 | 2,306,135,000 | 2,306,135,000 | 2,276,263,000 | 2,276,263,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|---------|--------|--------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 5,000 | 4,952 | 4,198 |
| Equity ratio | 48.71% | 51.48% | 60.52% |
| Debt-equity ratio | 105.29% | 94.25% | 65.22% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|--------|--------|--------|
| Tax Expense Rate | 39.18% | 11.72% | -4.75% |

Income statement

| | 2023 | 2022 | 2021 |
|----------------------------------------------------------------------|--------------|--------------|-------------|
| Turnover | 781,426,000 | 751,448,000 | 618,034,000 |
| Net income | -83,913,000 | -175,655,000 | 215,510,000 |
| EBIT | -101,365,000 | -176,079,000 | 228,532,000 |
| Operating income before taxes | -103,841,000 | -180,893,000 | 221,550,000 |
| Cash Flow | 33,951,000 | 203,106,000 | 122,237,000 |
| Net interest income | -2,476,000 | -4,814,000 | -6,982,000 |
| Research and development expenses | 112,529,000 | 76,642,000 | 72,200,000 |
| Income taxes | -40,680,000 | -21,202,000 | -10,530,000 |
| Result from investments in subsidiaries, associates and other | -20,752,000 | -15,964,000 | -16,570,000 |
| Revenues per employee | 156,285 | 151,746 | 147,221 |

Board of Directors

| | |
|-------------------------|-------------------------------|
| Iris Löw-Friedrich | Chairman of Supervisory Board |
| Constanze Ulmer-Eilfort | Member of Supervisory Board |
| Duncan McHale | Member of Supervisory Board |
| Camilla Languille | Member of Supervisory Board |
| Roland Sackers | Member of Supervisory Board |
| Wesley Wheeler | Member of Supervisory Board |

Members of Management Board

| | |
|-----------------|-------------------------------|
| Mario Polywka | Chairman of Managing Board |
| Cord Dohrmann | Member of Executive Committee |
| Craig Johnstone | Member of Executive Committee |
| Matthias Evers | Member of Executive Committee |
| Aurelie Dalbiez | Member of Executive Committee |
| Laetitia Rouxel | Member of Executive Committee |